Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M. Syeda(NYU Langone Health), David Polsky(New York University), James H. Garrett(Carnegie Mellon University), Michael Smylie(Inserm), A. Hauschild(University Hospital Schleswig-Holstein), Saim Ali(NYU Langone Health), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Monique Tan(Heidelberg University), G. M. Manikhas(City Clinical Oncology Center), Maya Dajee(Novartis (United States)), Michael Millward(The University of Western Australia), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Sachin Bajirao Adnaik(Princess Alexandra Hospital), Georgina V Long(The University of Sydney), Victoria Atkinson(Greenslopes Private Hospital), Jennifer Wiggins(New York University), Dummer Reinhard(University Hospital Zurich), Mario Mandalà(University of Perugia)
Cited by 28
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k